CHMA News

Strongbridge Biopharma, a late-stage biotech developing therapies for rare endocrine disorders, slashed the proposed deal size for its upcoming IPO on Wednesday. It also removed lead left bookrunner BofA Merrill Lynch. The Trevose, PA-based company now plans to raise $25 million by offering 2.5 million shares at $10 per share. Its shares are quoted on the Norwegian OTC under...read more

Strongbridge Biopharma, which is in-licensing and developing therapies for rare endocrine disorders, announced terms for its US IPO on Monday. The Trevose, PA-based company plans to offer 4.25 million shares, which would raise $76 million at its current converted price of $17.93 per share on the Norwegian OTC market. At that price, Strongbridge Biopharma would command a...read more

Cortendo, which is in-licensing and developing therapies for rare endocrine disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering. Its stock currently trades on the Norwegian OTC market under the symbol CORT with a market cap of over $300 million. The Trevose, PA-based company, which was founded in 1996, plans to list on the...read more

The IPO market saw sevens this past week. Seven IPOs raised $700 million. Cybersecurity firm Rapid7 spiked 56% on its offering, while cancer biotech ProNAi Therapeutics (+76%) had the seventh-best debut of 2015 and home phone provider Ooma had the seventh-worst. Small deal sizes - each under $150 million - became bigger as five companies priced above the midpoint. Just one...read more